Shijiazhuang Yongxing Pharmaceutical Group: It is recommended to list the innovative H-shares, which will result in a decrease of about 8.46% in the company's shareholding ratio.

Jin10 Data, September 30 - Shiyao Group announced that its indirectly non-wholly owned subsidiary, Shiyao Innovation, has been approved for its proposed listing of H-shares on the Main Board of the Stock Exchange. It is expected that following the completion of the proposed H-share listing, Shiyao Innovation will continue to be an indirect subsidiary of the company. The proposed H-share listing will involve an initial public offering of new H-shares by Shiyao Innovation on the Main Board of the Stock Exchange, accounting for no more than 10% of Shiyao Innovation's expanded issued share capital immediately following the completion of the proposed H-share listing (assuming the over-allotment option is not exercised). The issuance and allocation of shares under the proposed H-share listing will result in a decrease of approximately 8.46% in the company's equity percentage in Shiyao Innovation (assuming that 10% of Shiyao Innovation's expanded issued share capital will be issued immediately following the completion of the proposed H-share listing and that the over-allotment option will be fully exercised).